Article
International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?
Section of Environment and Radiation, International Agency for Research on Cancer (IARC), Lyon, France; Association of Dermatological Prevention (ADP) e.V., Hamburg, Germany; EUROSKIN e.V., Buxtehude, Germany. .
International Journal of Cancer (impact factor:
5.44).
04/2012;
DOI:10.1002/ijc.27616
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: New landscape in the treatment of melanoma: a 2012 update
[show abstract] [hide abstract]
ABSTRACT: The possibilities in treating melanoma patients changed dramatically in the last few years. Several new immunotherapies and targeted therapies have demonstrated promising antitumor activity with manageable side effects in patients with advanced melanoma. These include ipilimumab and PD-1(L) antibodies, and the targeted agents vemurafenib (BRAF-inhi- bitor), dabrafenib (BRAF-inhibitor), and trametinib (MEK-inhibitor). Although early clinical trials have not indicated that any of these offers a “breakthrough” in terms of antitumor activity for all patients, each will likely offer incremental improvements over standard care. Complex immunotherapies with adoptive T-cell transfer after nonmyeloablative lymphodeple- tion suggest response rates that are extraordinary; however, these results were derived from highly selected patient cohorts in single centers only. In the adjuvant setting interferon-α is still considered standard of care for high-risk melanoma patients. However, improvement rates for overall survival are still low. Therefore, sufficient markers for selection of patients who will profit from interferon-α are urgently needed. New drugs such as ipilimumab and BRAF/MEK inhibitors are already in clinical trials in the adju- vant setting, and may probably improve the possibilities to treat patients being at high risk for recurrence in a few years.ONCOLOGIE 02/2013; · 0.12 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
39 population-based cancer registries
age-period-cohort models
age-truncated standardized incidence rates
annual percentage change
birth cohort effect
certain populations
cohort-specific variations
cutaneous malignant melanoma
European countries
global patterns
incidence rate ratios
Incidence rates
melanoma trends
New Zealand
period-related influence
predominately fair-skinned populations
Rates
time trends
Western European countries
youngest age group